Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential
This study investigated the potential contraceptive effects of interrupting endometrial maturation with an antiprogesterone during the early luteal phase, without altering hormonal profiles.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (27)
- Accelerated dissolution of luteal-endometrial integrity by the administration of antagonists of gonadotropin-releasing hormone and progesterone to late-luteal phase women via openalex
- Dating the Endometrial Biopsy via openalex
- Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis via openalex
- Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486. via openalex
- Inhibition of the Estradiol-Mediated Endometrial Gland Formation by the Antigestagen Onapristone in Rabbits: Relationship to Uterine Estrogen Receptors via openalex
- Late Luteal Phase Administration of RU486 for Three Successive Cycles Does Not Disrupt Bleeding Patterns or Ovulation* via openalex
- The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium via openalex
- doi:10.1016/s0015-0282(16)49168-5 via openalex
- doi:10.1016/s0015-0282(16)54183-1 via openalex
- doi:10.1126/science.2781282 via openalex
- doi:10.1016/s0015-0282(16)30061-9 via openalex
- doi:10.1016/0002-9378(90)90784-5 via openalex
- W2409942517 via openalex
- doi:10.1056/nejm198701223160404 via openalex
- doi:10.1073/pnas.81.12.3879 via openalex
- doi:10.1016/s0015-0282(16)53174-4 via openalex
- doi:10.1210/jcem-66-3-508 via openalex
- doi:10.1210/jcem-71-4-1074 via openalex
- doi:10.1016/s0015-0282(16)61027-0 via openalex
- doi:10.1016/s0015-0282(16)60307-2 via openalex
- doi:10.1016/s0015-0282(16)60067-5 via openalex
- doi:10.1210/jcem-67-2-334 via openalex
- doi:10.1210/jcem-65-6-1135 via openalex
- doi:10.1016/s0015-0282(16)60375-8 via openalex
- doi:10.1093/oxfordjournals.humrep.a137111 via openalex
- doi:10.1016/s0015-0282(16)59944-0 via openalex
- doi:10.1210/jcem-67-1-80 via openalex
Cited by (4)
- Safety, tolerability, and pharmacokinetics of a novel, selective antiprogestagen (Org 31710) in healthy male volunteers 1998
- Mifepristone: Clinical Application in General Gynecology 1996
- Various uses of mifepristone in gynaecology and obstetrics 1996
- Endometrial effects of long-term low-dose administration of RU486 1995
Source provenance
- openalex
- last seen: 2026-05-13T18:37:28.025090+00:00